Retatrutide Results: What Clinical Trials Show

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that has no marketing authorisation in the UK or elsewhere. Questions about how long to see results from retatrutide can only be partially addressed through clinical trial data, which reflect outcomes in closely monitored research populations rather than individual experience. Phase 2 trial findings published in 2023 reported progressive body weight changes over 48 weeks, and the ongoing Phase 3 programme will provide further evidence. This article outlines what trial data currently show, the known side effects, and why the medicine remains available only within authorised clinical trials.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, with no MHRA marketing authorisation. It cannot be prescribed or supplied outside an authorised clinical trial in the UK.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it cannot be prescribed or supplied outside an authorised clinical trial.^[1] It is an investigational medicine developed by Eli Lilly that acts simultaneously on three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors.^[3][4] This triple agonist mechanism is designed to influence appetite regulation, energy expenditure and glucose metabolism through complementary pathways. Because it targets three receptors rather than the one or two targeted by currently licensed medicines, researchers have been studying whether this broader action produces different metabolic effects.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for authorising medicines. Retatrutide has not received MHRA authorisation, and no date for any application or decision can be given. Anyone who encounters retatrutide being sold online or outside a formal trial setting should be aware that such a product would not be a licensed medicine and could be falsified or unsafe. If you are interested in licensed weight-management treatments, these can be discussed with your GP.

What did clinical trials report about weight loss timelines?

A Phase 2 trial reported progressive body weight reductions over 48 weeks, with greater reductions at higher doses and later time points. These are preliminary findings; Phase 3 data from the TRIUMPH and TRANSCEND trials will provide more robust evidence.

Clinical trial data on retatrutide cannot answer how long an individual would take to see results, because the medicine is investigational and results are specific to the trial populations and conditions studied. A Phase 2 trial published in the New England Journal of Medicine in 2023 enrolled adults with obesity or overweight and reported body weight reductions over a 48-week treatment period, with participants receiving different dose levels under closely monitored conditions.^[3][4] The trial found that weight changes were progressive across the study duration, with greater reductions observed at higher doses and at later time points, though the trial was not designed to establish when any individual participant first noticed a change.^[3][4]

The Phase 3 programme, which includes the TRIUMPH and TRANSCEND trials, is now reporting data and will provide more robust evidence across larger and more diverse populations.^[5][6] These trials are designed to assess efficacy and safety over longer periods and in people with different health profiles, including those with type 2 diabetes. Until Phase 3 data are fully published and independently reviewed, the Phase 2 findings should be understood as preliminary. No comparison with currently licensed medicines such as semaglutide or tirzepatide can be drawn from these results, as the trials were not conducted head-to-head.

What are the known and suspected side effects to watch for?

The most commonly reported side effects in Phase 2 were gastrointestinal, including nausea, vomiting, diarrhoea and constipation. The full safety profile is still being characterised through ongoing Phase 3 trials.

The safety profile of retatrutide is still being characterised through ongoing clinical trials, and no complete picture is yet available. In the Phase 2 trial, the most commonly reported adverse effects were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation.^[3][4] These are consistent with the class effects seen with other GLP-1 receptor agonists and were generally reported as mild to moderate.^[7] Injection-site reactions were also noted.

Because retatrutide also acts on glucagon receptors, its full safety profile may differ from that of dual or single agonists, and this is one reason why the Phase 3 programme is important. Participants in clinical trials are monitored closely by the trial team, and any adverse events must be reported through the study protocol. Suspected side effects from medicines, including those taken within a clinical trial, can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Women of childbearing potential should be aware that participants who are pregnant, breastfeeding or planning a pregnancy are excluded from retatrutide trials. Appropriate contraception is required for trial participation. If you experience any concerning symptoms during a trial, contact the trial team promptly. For urgent medical concerns, contact NHS 111 for advice, or call 999 if you believe you are in immediate danger.

Why is retatrutide only available in clinical trials right now?

Retatrutide has not completed the regulatory process required for MHRA marketing authorisation, so it can only be accessed within authorised clinical trials. NICE would only consider it for NHS use after authorisation is granted.

Retatrutide is available only within authorised clinical trials because it has not yet completed the regulatory process required for a marketing authorisation. Before any medicine can be prescribed or supplied to the general public in the UK, the MHRA must review evidence from clinical trials demonstrating that the medicine is safe, effective and of acceptable quality for its intended use.^[2] Retatrutide has not yet reached that stage, and no authorisation has been granted.

Clinical trials serve a specific and essential function: they generate the controlled, monitored evidence that regulators need to make authorisation decisions. Participants in these trials are enrolled according to strict eligibility criteria, receive the medicine under medical supervision, and are followed up systematically so that both benefits and harms can be measured accurately. This process protects participants and ensures that any medicine that eventually reaches patients has been properly evaluated.

NICE, which makes recommendations on whether medicines should be used within the NHS, would only consider retatrutide after MHRA authorisation.^[11][12] Local commissioning decisions by Integrated Care Boards (ICBs) would follow from any NICE guidance.^[14][15] Until these steps are completed, retatrutide remains an investigational medicine. Anyone who sees it advertised or offered for sale outside a formal trial should treat this with serious caution, as such a product would not be subject to the quality controls applied to authorised medicines.

Frequently Asked Questions